N Engl J Med 2020 May 14
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
ABSTRACT
BACKGROUND
The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.
METHODS
In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until unacceptable toxic effects occurred or there was a loss of clinical benefit. The coprimary end points were overall survival and progression-free survival in the intention-to-treat population, as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).
RESULTS
The intention-to-treat population included 336 patients in the atezolizumab-bevacizumab group and 165 patients in the sorafenib group. At the time of the primary analysis (August 29, 2019), the hazard ratio for death with atezolizumab-bevacizumab as compared with sorafenib was 0.58 (95% confidence interval [CI], 0.42 to 0.79; P<0.001). Overall survival at 12 months was 67.2% (95% CI, 61.3 to 73.1) with atezolizumab-bevacizumab and 54.6% (95% CI, 45.2 to 64.0) with sorafenib. Median progression-free survival was 6.8 months (95% CI, 5.7 to 8.3) and 4.3 months (95% CI, 4.0 to 5.6) in the respective groups (hazard ratio for disease progression or death, 0.59; 95% CI, 0.47 to 0.76; P<0.001). Grade 3 or 4 adverse events occurred in 56.5% of 329 patients who received at least one dose of atezolizumab-bevacizumab and in 55.1% of 156 patients who received at least one dose of sorafenib. Grade 3 or 4 hypertension occurred in 15.2% of patients in the atezolizumab-bevacizumab group; however, other high-grade toxic effects were infrequent.
CONCLUSION
In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT03434379.).
Related Questions
New answer by Medical Oncologist at University of Texas MD Anderson Cancer Center (November 20, 2020)
Yes, this is applicable to patients who are on single agent immunotherapy, since the atezo/bev combination carries different mechanism of synergistic potential than single age...
Do you screen even asymptomatic patients?
New answer by Medical Oncologist at Geffen School of Medicine at UCLA (November 10, 2020)
Per the trial, this was required within 6 months of starting the study. However, in practice, I don't know that this strict rule would be necessary. For example, what if an EG...
ex. VEGFR2 expression, inflammatory signature, PDL1, etc.
New comment by Medical Oncologist at University of Texas MD Anderson Cancer Center ( November 28, 2020)
Further studies are required for the value of PDL-1 as a predictive biomarker.
In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?
New answer by Medical Oncologist at Keck School of Medicine of USC (November 18, 2020)
Unresectable HCC represents a broad group of HCC patients. For patients with liver limited disease without vascular invasion, I rely on tumor burden to determine whether to st...
New answer by Medical Oncologist at Keck School of Medicine of USC (November 12, 2020)
Patients with hepatitis B should be on antiviral therapy with HBV DNA level of 500 or less; all trials with immune checkpoint inhibitors have had such a requirement. There are...
New answer by Medical Oncologist at Vanderbilt University Medical Center (March 1, 2021)
The platelet eligibility for IMBrave150 was 75K, I believe. Eligibility in the original SHARP trial was 60K, so I often consider somewhere around 60K. Although if truly no var...
New answer by Medical Oncologist at St Lukes Cancer Care Assocs (March 28, 2021)
I have not been using Bev. that much in NSCLC.
The patient was started on a beta blocker, as this is standard in the area.
New answer by Medical Oncologist at University Hospitals (September 14, 2021)
It’s very important to treat varices before initiating bevacizumab in this patient population. Phase 3 trial specifically excluded patients with untreated varices. In th...
Would the etiology of HCC affect your decision, e.g. non-viral hepatitis since less benefit was shown for this group in IMbrave150?
New answer by Medical Oncologist at Keck School of Medicine of USC (November 2, 2021)
This is a challenging area where we need more definitive studies. With the info available, I do favor systemic therapy for such patients. Liver directed therapy is unlikely to...
New answer by Medical Oncologist at NYU Grossman School of Medicine (November 1, 2022)
Updated answer - April 29, 2024Selecting the first-line treatment for advanced hepatocellular carcinoma (HCC) involves considering various factors including the extent of the ...